A strong demand has emerged in the life science industry for enabling technologies that can generate, analyze, and interpret genomics and proteomics data much more quickly and cost effectively than currently possible otherwise. Molecular Staging Inc. (MSI), a life sciences company, is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.

These technologies are transformational because there has never before been a powerful molecular amplification method for proteins, or an effective whole genome amplification method…and because the technology platform combines unprecedented sensitivity and multiplexing advantages. MSI technologies, combined with sophisticated bioinformatics, broadly enable a wide range of products and services across multiple health care markets.

These products and services include:

High-coverage protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins simultaneously

Whole-genome amplification that allows DNA samples to be renewable resources, enabling researchers to return to them again and again for new tests or confirmatory diagnoses

Ultra-sensitive, multiplexed diagnostics that enable earlier detection of disease and reduced costs